L'Endocrinologo

, Volume 19, Issue 1, pp 15–20 | Cite as

Tomografia a emissione di positroni con 18F-fluorodesossiglucosio nel carcinoma tiroideo radioiodio-refrattario

Rassegna
  • 13 Downloads

Sommario

La capacità di captare e organificare lo iodio diminuisce progressivamente nelle forme meno differenziate del carcinoma tiroideo. Viceversa, il metabolismo glucidico è conservato/moderatamente incrementato nei carcinomi differenziati ed aumentato nelle neoplasie aggressive o de-differenziate dell’epitelio follicolare. Conseguentemente l’impiego della 18FDG-TEP/TC è particolarmente utile nel work-up iniziale, stratificazione prognostica e valutazione della risposta al trattamento dei carcinomi aggressivi (carcinomi poco differenziati e carcinoma anaplastico). Inoltre, la metodica è indicata nei pazienti con carcinoma tiroideo ad esordio differenziato quando si sospetti un viraggio verso le de-differenziazione e la radioiodio-resistenza.

Parole chiave

Carcinoma tiroideo Radioiodio 18F-fluorodesossiglucosio Tomografia ad emissione di positroni 

Notes

Conflitti di interesse

L’autore Luca Giovanella dichiara di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2018_395_MOESM1_ESM.doc (30 kb)
(DOC 30 kB)
40619_2018_395_MOESM2_ESM.doc (30 kb)
(DOC 30 kB)

Bibliografia

  1. 1.
    Grabellus F, Nagarajah J, Bockisch A et al. (2012) Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 37:121–127 CrossRefPubMedGoogle Scholar
  2. 2.
    Dong MJ, Liu ZF, Zhao K et al. (2009) Value of 18F-FDG-PET/ PET-TC in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 30:639–650 CrossRefPubMedGoogle Scholar
  3. 3.
    Freudenberg LS, Antoch G, Frilling A et al. (2008) Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/TC and FDG-PET. Eur J Nucl Med Mol Imaging 35:950–957 CrossRefPubMedGoogle Scholar
  4. 4.
    Wang W, Larson SM, Fazzari M et al. (2008) Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107–1113 Google Scholar
  5. 5.
    Robbins RJ, Wan Q, Grewal RK et al. (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498–505 CrossRefPubMedGoogle Scholar
  6. 6.
    Giovanella L, Ceriani L, De Palma D et al. (2012) Relationship between serum thyroglobulin and 18FDG-PET/TC in 131I-negative differentiated thyroid carcinomas. Head Neck 34:626–631 CrossRefPubMedGoogle Scholar
  7. 7.
    Giovanella L, Trimboli P, Verburg FA et al. (2013) Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/TC scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 40:874–880 CrossRefPubMedGoogle Scholar
  8. 8.
    Ma C, Xie J, Lou Y et al. (2010) The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. Eur J Endocrinol 163:177–183 CrossRefPubMedGoogle Scholar
  9. 9.
    Haugen BR, Alexander EK, Bible KC et al. (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1–133 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Poisson T, Deandreis D, Leboulleux S et al. (2010) 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 37:2277–2285 CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Clinica di Medicina Nucleare e Centro Diagnosi e Terapia delle Malattie TiroideeIstituto Oncologico della Svizzera ItalianaBellinzonaSvizzera

Personalised recommendations